.svg){kind=small}
Aug-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has demonstrated consistent performance in the New York market within the Tincture & Sublingual category. Over the months from May to August 2025, their ranking has remained steady, fluctuating between the 8th and 9th positions. This consistency suggests a stable consumer base and possibly a strong brand loyalty in this category. Notably, the brand maintained its 9th position in both May and August, with a slight improvement to 8th in July, indicating a brief but notable increase in consumer interest or sales efforts during that period. This movement is crucial as it highlights the brand's ability to remain competitive in a saturated market.
Despite the apparent stability in rankings, Canna Clinicals experienced a notable drop in sales from July to August 2025. This decline could be attributed to seasonal trends, increased competition, or shifts in consumer preferences. However, it is important to note that the brand consistently remained within the top 10, which is a significant achievement in a highly competitive environment. The absence of Canna Clinicals from the top 30 in other states or categories could be seen as a limitation to their market reach, suggesting potential areas for growth and expansion. This underlines the importance of strategic planning to enhance their presence in other regions and categories within the cannabis industry.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has experienced fluctuations in its market position over the past few months. Starting from May 2025, Canna Clinicals was ranked 9th, maintaining this position in June, before climbing to 8th in July, and then dropping back to 9th in August. This fluctuation in rank is indicative of the dynamic nature of the market, with competitors like High Falls Canna New York consistently outperforming Canna Clinicals, holding steady at 6th and 7th positions throughout the same period. Meanwhile, Jumbodose has shown a similar pattern to Canna Clinicals, maintaining a stable presence around the 8th and 9th ranks. Notably, Harney Brothers Cannabis entered the top 20 in July and August, indicating potential emerging competition. Canna Clinicals' sales peaked in June but saw a decline by August, suggesting a need for strategic adjustments to regain momentum and improve its competitive standing.
Notable Products
In August 2025, Canna Clinicals' top-performing product was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml) in the Tincture & Sublingual category, maintaining its number one rank consistently from May to August, with sales of $317. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) also held its second-place position throughout the same period. Max Strength Capsules 10-Pack (100mg CBD, 100mg THC) remained third in rank, despite a noticeable sales drop in August. The CBD/THC Balance Tincture (100mg CBD, 500mg THC) entered the rankings for the first time in August at fourth place. The CBD/THC/CBN 1:1:1 Sleep Complex Capsules 20-Pack (100mg CBD, 100mg THC, 100mg CBN) slipped from fourth to fifth place over the months from May to August.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
